EDIT News and Press, Editas Medicine Inc. From 05/16/23

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. Mr. Lucera will succeed Miche...

2023-05-16 15:43:09 ET Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference 2023 May 16, 2023 10:30 AM ET Company Participants Gilmore O'Neill – Chief Executive Officer Baisong Mei – Senior Vice President and Chief Medical Offic...

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and efficacy clinical data from the Phase 1/2 RUBY trial of EDIT-301 in patients with severe sickle ce...

2023-05-05 16:39:40 ET Summary Editas Medicine, Inc. focuses on gene-editing using CRISPR technology to develop medicines for previously untreatable or under-treated diseases. The company's leading product, EDIT-301, aims to treat sickle cell disease (SCD) and transfusion-dependen...

2023-05-04 12:39:28 ET Editas Medicine ( NASDAQ: EDIT ) is scheduled to announce Q1 earnings results on Friday, May 5th, before market open. The consensus EPS Estimate is -$0.81 and the consensus Revenue Estimate is $3.29M (-51.4% Y/Y). Over the last 1 year, EDIT has...

2023-05-04 11:16:58 ET Major earning expected before the bell on Friday include: AMC Entertainment Holdings ( AMC ) Dominion Energy ( D ) Enbridge ( ENB ) fuboTV ( FUBO ) Warner Bros. Discovery ( WBD ) For further details see: Notable earn...

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the comprehensive data from a study of the proprietary SLEEK (SeLection by Essential-gene Exon ...

CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 an...

2023-04-27 09:24:19 ET The US FDA has granted Orphan Drug status to EDIT-301, Editas Medicines' ( NASDAQ: EDIT ) gene editing therapy for sickle cell disease. The treatment already had the status for beta thalassemia. EDIT-301 also has Rare Pediatric Disease des...

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the trea...